GENX Fundamental Analysis - GENIX PHARMACEUTICALS CORP

Fundamental Rating

Overall GENX gets a fundamental rating of 0 out of 10. We evaluated GENX against 4 industry peers in the Personal Care Products industry. Both the profitability and financial health of GENX have multiple concerns. GENX is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

GENX had negative earnings in the past year.

GENX had a negative operating cash flow in the past year.

GENX had negative earnings in each of the past 5 years.

GENX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of GENX (-214.87%) is worse than 75.00% of its industry peers.

		Industry Rank	Sector Rank
ROA	-214.87%
ROE	N/A
ROIC	N/A

ROA(3y)-717.5%

ROA(5y)-440.12%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a Gross Margin value of 30.00%, GENX perfoms like the industry average, outperforming 50.00% of the companies in the same industry.

GENX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	30%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

GENX does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, GENX has about the same amount of shares outstanding.

GENX has more shares outstanding than it did 5 years ago.

The debt/assets ratio for GENX is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -313.32, we must say that GENX is in the distress zone and has some risk of bankruptcy.

GENX has a Altman-Z score of -313.32. This is in the lower half of the industry: GENX underperforms 75.00% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-313.32

ROIC/WACCN/A

WACC6.33%

2.3 Liquidity

A Current Ratio of 0.04 indicates that GENX may have some problems paying its short term obligations.

GENX has a worse Current ratio (0.04) than 75.00% of its industry peers.

GENX has a Quick Ratio of 0.04. This is a bad value and indicates that GENX is not financially healthy enough and could expect problems in meeting its short term obligations.

GENX has a worse Quick ratio (0.04) than 75.00% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.04
Quick Ratio	0.04

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

GENX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 97.20%, which is quite impressive.

The Revenue for GENX has decreased by -63.30% in the past year. This is quite bad

Measured over the past years, GENX shows a very negative growth in Revenue. The Revenue has been decreasing by -50.46% on average per year.

EPS 1Y (TTM)97.2%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-80%

Revenue 1Y (TTM)-63.3%

Revenue growth 3YN/A

Revenue growth 5Y-50.46%

Sales Q2Q%-100%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

GENX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GENIX PHARMACEUTICALS CORP

TSX-V:GENX (5/28/2025, 7:00:00 PM)

0.035

+0.01 (+16.67%)

Chartmill FA Rating

GICS SectorConsumer Staples

GICS IndustryGroupHousehold & Personal Products

GICS IndustryPersonal Care Products

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst OwnersN/A

Inst Owner ChangeN/A

Ins Owners19.24%

Ins Owner ChangeN/A

Market Cap2.07M

Analysts0

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	518.18
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)0

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)0

FCFYN/A

OCF(TTM)0

OCFYN/A

SpS0

BVpS-0.02

TBVpS-0.02

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-214.87%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	30%
FCFM	N/A

ROA(3y)-717.5%

ROA(5y)-440.12%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0.07

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.04
Quick Ratio	0.04
Altman-Z	-313.32

F-Score4

WACC6.33%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)97.2%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-80%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-63.3%

Revenue growth 3YN/A

Revenue growth 5Y-50.46%

Sales Q2Q%-100%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y64.86%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y14.77%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y13.6%

OCF growth 3YN/A

OCF growth 5YN/A

GENIX PHARMACEUTICALS CORP (GENX.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens